Advancements in Antibody-Drug Conjugates for Cancer Therapy
Author Information
Author(s): Qiang Yang, Yunpeng Liu
Hypothesis
Fc-glycan-specific antibody-drug conjugates (gsADCs) can improve the efficacy and safety of cancer treatments.
Conclusion
Fc-glycan-specific ADCs show promising results in clinical trials, indicating their potential to enhance cancer therapy.
Supporting Evidence
- JSKN003 and IBI343 have shown promising results in phase 1 trials.
- IBI343 received fast-track designation by the FDA for pancreatic cancer treatment.
- gsADCs have demonstrated comparable or superior efficacy to traditional ADCs in preclinical studies.
Takeaway
Scientists are making better cancer treatments by attaching drugs to antibodies in a special way that helps them work better and cause fewer side effects.
Methodology
The article reviews various glycan-specific conjugation techniques and discusses the development stages of several gsADCs.
Limitations
Increased manufacturing costs and potential challenges in large-scale production of gsADCs.
Participant Demographics
Patients with advanced gastric/gastroesophageal junction adenocarcinoma and other solid tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website